Seer Q2 revenue $4M (+11% YoY); slashes FY2023 guidance to $16-18M from $23-25M

Seer, Inc.

2023-Q2 EPS reported -$0.74 revenue$8,061,000

Net loss widened to $23.4M from $22.8M YoY; operating expenses rose 21% to $30.2M.
Product-related revenue $3.0M including $1.4M related party; service revenue $467K; grant $538K.
Cash, equivalents and investments at $396M as of June 30, 2023.
Launched Proteograph XT Assay Kit and STAC service; expanded Thermo Fisher collaboration.
Guidance cut: now expects FY2023 revenue $16-18M (prior $23-25M), 10% growth at midpoint.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Seer, Inc. reported the second quarter ended June 30, 2023 results: revenue $4.0 million. Guidance lowered.

Period: the second quarter ended June 30, 2023
Revenue: $4.0 million
Guidance: lowered
Result: reported results

Exact text from the filing

commercializing a disruptive new platform for proteomics, today reported financial results for the second quarter ended June 30, 2023. Recent Highlights • Achieved revenue of $4.0 million for the second quarter of 2023, an increase of 11% over the prior year period • Launched the Proteograph XT Assay Kit, enabling rapid proteomics across a range of sample types

View on SEC.gov

Browse all earnings releases →

Seer, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-028203

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.